SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults.
Document Type
Article
Publication Date
1-3-2024
Publication Title
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Keywords
washington; swedish; renton; covid-19
Abstract
Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.
Department
Infectious Diseases
Department
Population Health
Recommended Citation
Levy, Matthew E; Burrows, Evanette; Chilunda, Vanessa; Pawloski, Pamala A; Heaton, Phillip R; Grzymski, Joseph; Goldman, Jason D; McEwen, Lisa M; Wyman, Dana; Dei Rossi, Andrew; Dai, Hang; Isaksson, Magnus; Washington, Nicole L; Basler, Tracy; Tsan, Kevin; Nguyen, Jason; Ramirez, Jimmy; Sandoval, Efren; Lee, William; Lu, James; and Luo, Shishi, "SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults." (2024). Articles, Abstracts, and Reports. 8461.
https://digitalcommons.providence.org/publications/8461
